F�r a fe� �eca�es,� ar�un� the mi��le �f the 20 th century,� there �as �i�es�rea� ��timism that science c�ul� �in the fi�ht a�ainst infecti�us �iseases,� re�uce their s�rea� an� the �ama�e they �� t� the infecte�,� an� even era�icate s�me. Penicillin became available in the 1940s an�,� in the �eca�es after that,� m�re an� m�re antibi�tics �ere �evel��e� an� successfully use� in the fi�ht a�ainst �isease. On a se�arate fr�nt,� the successful era�icati�n �f small��x thr�u�h vaccinati�n sh��e� that �isease threats can be eliminate�. H��ever,� by the en� �f the 20 th century,� small��x remaine� the �nly exam�le �f era�icati�n,� ne� �ath��ens emer�e�,� an� many �l� f�es,� such as tubercul�sis,� sa� a resur�ence.
Furtherm�re,� scientists f�un� that bacterial �ath��ens �evel�� resistance a�ainst existin� antibi�tics as fast as the �harma in�ustry can �evel�� ne� �nes. This threat �i�n't arise entirely fr�m natural causes. It became clear in the 1990s that the �i�es�rea� misuse an� �veruse �f antibi�tics,� such as their blanket use in a�riculture,� create� the envir�nments �here micr�bial strains are enc�ura�e� t� �ass ar�un� existin� resistance traits an� even t� �evel�� ne� �nes.
F�r a �hile,� the in�ustry trie� t� kee� u� the race an� �evel��e� ne� antibi�tics,� but in recent years,� the �i�eline �rie� u�. As Laura Pi���ck fr�m the Antimicr�bial A�ents Research Gr�u� at the University �f Birmin�ham ��inte� �ut in a c�mment f�r The Lancet last year,� n� m�re than three antibacterial a�ents �ere a��r�ve� since 2008,� c�m�are� �ith 16 in the years 1983 t� 1987.
Pi���ck lists several reas�ns f�r this �ecline in �ru� �evel��ment: "mer�ers bet�een �harmaceutical c�m�anies have re�uce� the number an� �iversity �f �ru�-�isc�very teams,� an� many c�m�anies have �ith�ra�n fr�m �evel��ment �f antibacterial �ru�s" she �rites. She als� ��ints �ut that initial h��es f�r �en�mics t� yiel� ne� tar�ets f�r antibacterial �ru�s have been �isa���inte�. Finally,� she ��ints �ut that f�r c�m�anies �evel��in� antibi�tics "the return �n investment is l�� because antibi�tics,� unlike many �ru�s,� are usually use� f�r sh�rt-term c�urses �f treatment (5-7 �ays)." T� im�r�ve the ec�n�mic viability �f such �ru�s she su��ests they mi�ht be s�l� at hi�her �rices,� es�ecially c�nsi�erin� the years �f life they save in c�m�aris�n t� m�re ex�ensive but less efficient cancer �ru�s. Alternatively,� ��vernments an� aca�emic instituti�ns c�ul� take u� m�re �f the research an� �evel��ment ��rk.
"This is the �ara��x �e fin� �urselves in,�" says Pi���ck,� "at the very time �e have the kn��le��e t� �esi�n ne� an� effective antibi�tics,� fe� �harmaceutical c�m�anies �ish t� �evel�� them. In all likelih���,� �isc�very an� early research �ill be by aca�emic researchers an� clinical research an� �evel��ment by the c�mmercial sect�r. T� �et this m��el ��rkin� effectively t� meet the bacterial infecti�n challen�es,� a ne� fun�in� m��el is require�."
What �as �nce the sin�le bi��est bacterial threat in in�ustrialise� c�untries,� the methicillin-resistant strains �f Staphylococcus aureus (MRSA),� seems t� have subsi�e� s�me�hat in the last fe� years. In 2011,� the number �f rec�r�e� cases �f MRSA infecti�ns fell t� a rec�r� l��. This si�nificant success is the result �f the attenti�n hea�e� �n MRSA an� similar Gram-��sitive bacteria �n all levels fr�m �ru� �evel��ment thr�u�h t� clinical �ractice. But in the meantime,� Pi���ck �ia�n�ses,� there is a "�enuine rarity �f a�ents t� treat infecti�ns cause� by Gram-ne�ative bacteria."
Gram-ne�ative bacteria inclu�e E. coli an� the �neum�nia �ath��en Klebsiella pneumoniae. Resistance traits kn��n as NDM-1 an� KPC,� Feature res�ectively,� make these bacteria resistant t� carba�enem antibi�tics an� c�ul� bec�me a threat in the future. As the �utbreak �f a �ath��enic E. coli strain in Germany in June 2011 has �em�nstrate� �nce m�re,� �an�er�us infecti�ns can c�me a��arently �ut �f n��here an� �reak hav�c even bef�re the me�ical ex�erts are able t� ��rk �ut �hat is ��in� �n.
The British S�ciety f�r Antimicr�bial Chem�thera�y has recently launche� a �l�bal initiative calle� Antibi�tic Acti�n (htt�:// antibi�tic-acti�n.c�m/),� �hich aims at "Inf�rmin� all ab�ut the nee� f�r �isc�very,� �evel��ment an� a��r��riate use �f antibi�tic a�ents."
Alternatives to antibiotics
With hin�si�ht,� �ne mi�ht ar�ue that antibi�tics,� �ri�inally �evel��e� by fun�i,� �ere never ��in� t� �i�e �ut bacterial threats. After all,� bacteria have c�existe� �ith antibi�tic-�r��ucin� fun�i f�r hun�re�s �f milli�ns �f years an� survive� by �evel��in� suitable �efence mechanisms. An� �ith a �enerati�n s�an that may be as sh�rt as 30 minutes,� bacteria can ev�lve very quickly. In an attem�t t� by�ass the arms race bet�een antibi�tics �r��ucers an� their micr�bial tar�ets,� researchers are n�� c�nsi�erin� fun�amentally �ifferent s�luti�ns.
Mankin� is at risk �f l�sin� the fi�ht a�ainst infecti�us �isease,� as the success �f antibi�tics fa�es an� �e're still ill-�re�are� f�r ne� viral �an�emics. Michael Gross re��rts.
Fighting infections
Fighting disease: In the first �eca�es after the intr��ucti�n �f antibi�tics,� there �as �i�es�rea� ��timism that the fi�ht a�ainst infecti�us �isease c�ul� be ��n. This early a�vert f�r �enicillin �as tar�ete� at W�rl� War II servicemen. (Picture: Wiki�e�ia.) Firstly,� alth�u�h �en�mics has faile� t� �r�vi�e ne� miracle cures f�r infecti�us �iseases,� it may still save the �ay in c�mbinati�n �ith existin� �ru�s. If an� �hen �en�mic analysis at the ��int �f care bec�mes a r�utine �r�ce�ure,� ��ct�rs c�ul� establish the �recise nature �f a bacterial infecti�n inclu�in� the �resence �f any resistance traits. This ��ul� all�� them t� a��ly existin� �ru�s much m�re selectively an� efficiently. It ��ul� als� im�r�ve the c�st efficiency �f clinical trials f�r ne� antimicr�bial a�ents,� as �ne c�ul� select trial �r�u�s �ith infecti�ns fr�m a s�ecific,� �ell-�efine� �ath��en.
It may als� be a ���� i�ea t� a��ly �ru�s that ��n't kill bacteria but �nly su��ress �ath��enic traits such as t�xin secreti�n �r c�l�nisati�n �f their h�st. The fun�amental �ifference is that a �ru� that st��s,� f�r instance,� E. coli fr�m attachin� t� the human urinary tract �ith�ut killin� the bacteria ��esn't exert as much �f a selective �ressure as an antibi�tic that ��ses an a�a�t-�r-�ie threat t� the micr�bes,� an� theref�re ��ul�n't carry nearly as bi� a risk �f resistance �r�blems. Furtherm�re,� a��r�aches that �nly �isarm the �ath��en are less likely t� affect the 'frien�ly' bacteria in �ur intestines,� ex�erts believe.
One �r�misin� tar�et �f such alternative antimicr�bials is the assembly �f the �ili,� the 'hairs' that all�� bacteria t� bin� t� e�ithelia �f infecte� h�sts,� like E. coli ��es in urinary tract infecti�ns. Pili are self-assemblin� chains �f �r�tein subunits,� an� the mechanisms �f their assembly have been eluci�ate� in s�me �etail in recent years (Remaut et al. (2008) An�ther alternative that has ex�erience� a renaissance �f s�rts in recent years is the thera�eutic use �f bacteri��ha�es (Curr. Bi�l. (2011),� 21,� R267-R270). One si�nificant issue there is �hether the use �f mixtures �f �ha�es,� kn��n as �ha�e c�cktails,� is m�re efficient than that �f s�ecific sin�le s�ecies �f �ha�es.
"The ��tential ��rry in terms �f usin� �ha�e c�cktails is that they select f�r bacteria that are n�t �nly m�re resistant t� the �ha�es use� in the treatment,� but als� ne� �ha�es that they have n�t ex�erience�. In �ther ��r�s,� the c�cktail treatment mi�ht,� in fact,� select f�r a �eneral resistance mechanism,� makin� future treatment less effective,�" ex�lains Britt K�skella fr�m the University �f Exeter,� UK. "We teste� this i�ea usin� �ha�es that infect the �lant �ath��en,� Pseudomonas syringae �f t�mat�,� an� f�un� that usin� a c�cktail �i� n�t hin�er the ev�luti�n �f resistance. The ���� ne�s is that,� at least f�r the �ha�e c�mbinati�ns �e use�,� the c�cktail �i� n�t select f�r increase� resistance a�ainst future �ha�es,�" K�skella says. S� c�mbinin� �ha�es in a c�cktail treatment seems t� �� neither harm n�r ���� (Pr�c. R. S�c. B (2011),� ��i:10.1098/rs�b.2011.2259). H��ever,� her research als� f�un� that the c�st �f a�a�tin� t� multi�le �ha�es re�uces the fitness �f the survivin� bacterial strains,� c�m�are� �ith th�se that �nly ha� t� c��e �ith a sin�le �ha�e s�ecies.
Researchers have als� h��e� that antimicr�bial �e�ti�es �f the ty�e that �as first �isc�vere� in fr�� skin in the 1980s mi�ht be �evel��e� int� antimicr�bial �ru�s t� ste� in f�r tra�iti�nal antibi�tics. A recent fin�in� fr�m the �r�u� �f Michael Br�ckhurst at the University �f Liver���l,� h��ever,� may �eflate this h��e. The researchers f�un� that Staphylococcus aureus n�t �nly mana�e� t� �evel�� resistance t� the �e�ti�e �exi�anan,� a �ru� can�i�ate f�r �iabetic le�-ulcer infecti�ns,� but,� m�re ��rryin�ly,� in s�me instances als� �evel��e� cr�ss-resistance t� �efensin-1 �f human neutr��hils after bein� ex��se� t� the �e�ti�e. The results,� the researchers �rite "hi�hli�ht a �rave ��tential risk �f AMP thera�ies".
Viral threats
Mean�hile,� humanity is als� vulnerable t� infecti�us �iseases that antibi�tics can't �� anythin� ab�ut,� namely th�se �ri�inatin� fr�m viruses. Recent �utbreaks �f flu variants �ri�inatin� in animals inclu�in� bir�s an� s�ine have hei�htene� �ur a�areness �f the threat ��se� by viral z��n�ses,� i.e. �iseases that jum� the s�ecies barrier an� bec�me transmissible bet�een humans. This threat has been �ith us since the inventi�n �f a�riculture,� an� t��ay's mil� chil�h��� infecti�ns are the embers �f much m�re virulent �iseases that are als� believe� t� have c�me fr�m animals an� t� have �eakene� �ver centuries �f c�-ev�luti�n �ith their ne� human h�sts. H��ever,� t��ay's �l�bal travel habits increase the �an�er by makin� it ��ssible f�r a ne� �an�emic t� s�rea� ar�un� the �l�be in a sh�rt time.
A �articular cause f�r c�ncern lies in the avian flu strains carryin� the H5 haema��lutinin,� such as H5N1. This strain is �i�es�rea� am�n� bir�s in S�utheast Asia. Fr�m 2003 t� the en� �f 2011,� there �ere 578 c�nfirme� cases �f humans infecte� �ith this strain,� an� m�re than half (340) �f th�se infecte� �ie�. S� far,� all victims �f this strain have been infecte� by c�ntact �ith bir�s,� s� the virus seems t� be unable t� s�rea� fr�m �ne human t� an�ther,� e.�. via aer�s�ls. The ��rry is that if an H5 virus sh�ul� s�meh�� acquire the ability t� s�rea� bet�een humans,� the resultin� �an�emic c�ul� kill many milli�ns �f �e��le.
As the virus hasn't acquire� this ability yet,� s�me ex�erts ��timistically assume� it mi�ht be intrinsically unable t� �� s�. H��ever,� t�� research �r�u�s have n�� in�e�en�ently an� �n �ifferent �aths arrive� at a variant H5 virus that is easily transmissible bet�een ferrets,� the mammalian m��el system �f ch�ice f�r such stu�ies. This fin�in� b�th un�ermine� �ur sense �f security that the H5 �an�emic mi�ht never ha��en an� a��e� a ne� viral threat t� �ur c�llective fears,� namely that human-transmissible H5 viruses c�ul� be en�ineere� an� use� as bi��ea��ns.
The relevant �ublicati�ns by Y�shihir� Ka�a�ka's �r�u� at the University �f Wisc�nsin in Ma�is�n an� by R�n F�uchier's team at the Erasmus Me�ical Center in R�tter�am,� Netherlan�s,� have been acce�te� by Nature an� Science,� res�ectively,� but b�th j�urnals refraine� fr�m �ublishin� the full scientific �etails f�r fear they mi�ht �r�vi�e a blue�rint f�r bi��ea��ns. The j�urnals share� the results �ith the US Nati�nal Science A�vis�ry B�ar� f�r Bi�security (NSABB),� �hich rec�mmen�e� �ublicati�n �f the �a�ers in a re�acte� f�rm �ith�ut full �etails.
In a �etaile� statement �ublishe� b�th in Nature an� in Science,� the NSABB ackn��le��e� the im��rtance �f the ��rk,� �hich f�r the first time �em�nstrate� that H5 viruses can easily bec�me 
